论文部分内容阅读
目的 观察半年恢复期严重急性呼吸综合征 (SARS)患者血清中 SARS抗体对 SARS病毒介导细胞病变的抑制作用。方法 用酶联免疫吸附试验 (EL ISA)测定 12例 SARS恢复期患者血清中 SARS抗体 (Ig G)的吸光度 (A)值 ;用维持液按 1∶ 8稀释恢复期患者的血清 ,并与分离、培养和鉴定后不同稀释度的SARS病毒 (SARS Co )上清作用 ,再加入 Vero E6细胞悬液进行培养 ,观察 Vero E6细胞病变的程度。结果 12例恢复期患者半年前的 SARS抗体 A值范围为 0 .79～ 2 .0 1,半年后的 A值范围为 0 .81～ 2 .0 6。其加入 12例恢复期血清的 SARS Co Vero E6细胞病变程度至少降低 2 5 %以上。结论 SARS患者半年后恢复期血清的 SARS抗体滴度有上升趋势 ,它还可抑制 SARS病毒介导的细胞病变 ,对 SARS病毒有中和作用 ,推测 SARS抗体是一种保护性抗体
Objective To observe the inhibitory effect of SARS antibody in sera of patients with severe acute respiratory syndrome (SARS) on the SARS virus-mediated cytopathic effect (ICV) in six-year convalescence. Methods Serum SARS antibody (Ig G) absorbance (A) was measured by enzyme-linked immunosorbent assay (ELISA) in 12 patients with convalescent SARS. , Cultured and identified with different dilutions of the SARS virus (SARS Co) supernatant, and then added Vero E6 cell suspension for culture to observe the extent of Vero E6 cell lesions. Results Six months after the convalescence, the value of SARS antibody A ranged from 0.79 to 2.01 and the value of A ranged from 0.81 to 2.06 after six months. The degree of lesion of SARS Co Vero E6 cells added to 12 convalescent sera decreased by at least 25%. Conclusions The serum SARS antibody titers in the convalescent phase of SARS patients have an increasing tendency. It can also inhibit the SARS virus-mediated cytopathic effect and neutralize the SARS virus. It is presumed that the SARS antibody is a protective antibody